Peripheral arterial disease: Medical care and prevention of complications

Preventive Cardiology

Volumn 5, Issue 3, 2002, Pages 119-130

  Dawson, David L ^a,e   Hiatt, William R ^b   Creager, Mark A ^c   Hirsch, Alan T ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e NASA JOHNSON SPACE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMFEBUTAMONE; AMINOPHYLLINE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BUFLOMEDIL; CILOSTAZOL; CINNARIZINE; CLOPIDOGREL; CYANOCOBALAMIN; DEFIBROTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; FOLIC ACID; GINKGO BILOBA EXTRACT; INSULIN; KETANSERIN; METFORMIN; NAFTIDROFURYL; NICOTINE; NICOTINIC ACID; PENTOXIFYLLINE; PROGESTERONE; PYRIDOXINE; RAMIPRIL; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ANAMNESIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; DYSPEPSIA; EARLY DIAGNOSIS; EXERCISE; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LABORATORY DIAGNOSIS; LEG REVASCULARIZATION; LIMB ISCHEMIA; MEDICAL CARE; META ANALYSIS; MORBIDITY; OBESITY; PHYSICAL EXAMINATION; PHYSIOTHERAPY; POSTMENOPAUSE; PREVALENCE; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; TASK PERFORMANCE; VASCULAR SURGERY; VERTIGO; WALKING;

EID: 0036626915     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2002.00558.x     Document Type: Review

References (70)

1. Dormandy J, Rutherford R, eds. (Transatlantic Inter-Society Consensus [TASC] Working Group). Management of Peripheral Arterial Disease (PAD). J Vasc Surg. 2000;31:S1-S296.
2. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998;18:185-192.
3. Fowkes FG, Housley E, Caewood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J j Epidemiol. 1991;20:384-392.
4. Newman AB, Sutton-Tyrell K, Rutan GH, et al. Lower extremity arterial disease in elderly subjects with systolic hypertension. J Clin Epidemiol. 1991;44:15-20.
5. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. Circulation. 1993;88:837-845.
6. Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 1997;131:115-125.
7. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472-1479.
8. Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94:3026-3049.
9. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
10. Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;279:497-498.
11. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172-1181.
12. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47:1255-1256.
13. Tonelli C, Finzi G, Catamo A, et al. Prevalence and prognostic value of peripheral arterial disease in stroke patients. Int Angiol. 1993;12:342-343.
14. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159:387-392.
15. McDermott MM, Mehta S, Liu K, et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med. 1999;14:173-181.
16. McDermott MM, Fried L, Simonsick E, et al. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the Women's Health and Aging Study. Circulation. 2000;101:1007-1012.
17. Hiatt WR, Wolfel EE, Regensteiner JG, et al. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol. 1992;73:346-353.
18. McLafferty RB, Dunnington GL, Mattos MA, et al. Factors affecting the diagnosis of peripheral vascular disease before vascular surgery referral. J Vasc Surg. 2000;31(5):870-879.
19. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221-226.
20. Hirsch AT, Treat-Jacobsen D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med. 1997;2:243-251.
21. Dormandy J, Heeck L, Vig S. Intermittent daudicafion: a condition with underrated risks. Semin Vasc Surg. 1999;12:96-108.
22. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227:301-308.
23. Goldhaber S, Manson J, Stampfer M, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet. 1992;340:143-145.
24. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1998;296:320-331.
25. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
26. Juergens J, Barker N, Hines E. Arteriosclerosis obliterans: a review of 520 cases with special reference to pathogenic and prognostic factors. Circulation. 1960;21:188-195.
27. Smith I, Franks P, Greenhalgh R, et al. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischemia. Eur J Vasc Endovasc Surg. 1996;11:402-408.
28. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. JAMA. 1996;276:1409-1415.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet. 1998;352:854-865.
31. Valentine R, Grayburn P, Vega G, et al. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med. 1994;154:801-806.
32. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
33. Duffield R, Lewis B, Miller N, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis; a randomised controlled trial. Lancet. 1983;2:639-642.
34. Blankenhorn D, Azen S, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83:438-447.
35. de Groot E, Jukema J, van Boven A, et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol. 1995;76:40C-46C.
36. Olsson A, Ruhn G, Erikson U. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. J Intern Med. 1990;227:381-390.
37. Pedersen T, Kjekshus J, Pyörälä K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J CardioL 1998;81:333-335.
38. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269:3015-3023.
39. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
40. Freemantle N, Barbour R, Johnson R, et al. The use of statins: a case of misleading priorities? BMJ. 1997;315:826-828.
41. Solomon S, Ramsay L, Yeo W, et al. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ. 1991;303:1100-1104.
42. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151:1769-1776.
43. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
44. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
45. Boushey C, Beresford S, Omenn G, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
46. Nygard O, Nordrehaug J, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
47. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 1998;280:605-613.
48. Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg. 1991;5:291-304.
49. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Vasc Med. 1998;3:257-260.
50. Hiatt WR, Nawaz D, Regensteiner JG, et al. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil. 1988;12:525-532.
51. Hiatt WR, Regensteiner JG. Exercise rehabilitation in the treatment of patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:163-170.
52. Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise vs. strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90:1866-1874.
53. Regensteiner JG, Meyer TJ, Krupski WC, et al. Hospital vs. home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology. 1997;48:291-300.
54. Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81:602-609.
55. Hiatt WR. Medical treatment of claudication. In: Hirsch AT, ed. An Office-Based Approach to the Diagnosis and Treatment of Peripheral Arterial Disease. Part IV: Morbidity of PAD: Medical Approaches to Claudication. Belle Mead, NJ: Exerpta Medica; 1999:6-15.
56. Kimura Y, Tani Y, Knabe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35:1144-1149.
57. Elam MB, Heckman JR, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942-1947.
58. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-686.
59. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267-274.
60. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmocological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-2050.
61. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;209(17):523-530.
62. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104:66-72.
63. Lindgärde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation. 1989;80:1549-1556.
64. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J. 1996;155:1053-1059.
65. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol. 1988;26:569-576.
66. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135-146.
67. Dawson DL, Chow MS, Regensteiner JG, et al. Treating intermittent claudication secondary to peripheral arterial disease. Pharmacol Ther. 1999;24:616-623.
68. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg. 1999;178:141-146.
69. Zierler RE, Zierler BK. Duplex sonography of lower extremity arteries. Semin Ultrasound CT MR. 1997;18:39-56.
70. Schneider PA, Ogawa DY, Rush MP. Lower extremity revascularization without contrast arteriography: a prospective study of operation based upon duplex mapping. Cardiovasc Surg. 1999;7:699-703.